D. Lillicrap

发表

Advances in knowledge of inhibitor formation in severe haemophilia A

M. Cormier, P. Batty, J. Tarrant, 2020, British journal of haematology.

Sedimentation Velocity Analytical Ultracentrifugation of Oxidized Recombinant Full-Length Factor VIII

D. Lillicrap, P. Zakas, J. Healey, 2020, Frontiers in Immunology.

Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia

R. Blumberg, D. Lillicrap, 2018, Blood.

Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH

A. Iorio, F. Rosendaal, M. Makris, 2016, Journal of thrombosis and haemostasis : JTH.

Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A.

P. Moorehead, D. Lillicrap, B. Reipert, 2016, Blood.

Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity

S. Lacroix-Desmazes, J. Oldenburg, D. Lillicrap, 2015, Haematologica.

Rapid Acquisition of Immunologic Tolerance to Factor VIII and Disappearance of Anti-factor VIII IgG4 After Prophylactic Therapy in a Hemophilia A Patient With High-titer Factor VIII Inhibitor

P. Moorehead, D. Lillicrap, Lisa Thibeault, 2015, Journal of pediatric hematology/oncology.

Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010

M. Carcao, C. Infante-Rivard, D. Lillicrap, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity

A. Iorio, J. Astermark, G. Dolan, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Inhibitors – genetic and environmental factors

E. Santagostino, K. Fijnvandraat, D. Lillicrap, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

The Canadian "National Program for hemophilia mutation testing" database: a ten-year review.

J. Leggo, P. James, D. Lillicrap, 2013, American journal of hematology.

Low prevalence of inhibitor antibodies in the Canadian haemophilia population

M. Carcao, D. Lillicrap, J. St‐Louis, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Induction of partial immune tolerance to factor VIII through prior mucosal exposure to the factor VIII C2 domain

H. Weiner, D. Lillicrap, C. Hough, 2006, Journal of thrombosis and haemostasis : JTH.

Laboratory issues in bleeding disorders

F. Rodeghiero, A. Federici, D. Lillicrap, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age?

D. Lillicrap, M. Poon, C. Demers, 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

Factor IX Cardiff: a variant factor IX protein that shows abnormal activation is caused by an arginine to cysteine substitution at position 145

A. Bloom, D. Lillicrap, I. Peake, 1989, British journal of haematology.

Haemophilia B: database of point mutations and short additions and deletions.

P. Reitsma, K. High, R. Schwaab, 1990, Nucleic acids research.

A mutation adjacent to the beta cleavage site of factor IX (valine 182 to leucine) results in mild haemophilia Bm

A. Bloom, D. Lillicrap, I. Peake, 1990, British journal of haematology.

Mutations causing hemophilia B: direct estimate of the underlying rates of spontaneous germ-line transitions, transversions, and deletions in a human gene.

S. Sommer, C. Bottema, D. Koeberl, 1990, American journal of human genetics.

Practical Hemostasis and Thrombosis

M. Makris, D. O'shaughnessy, D. Lillicrap, 2008 .

Aberrant Splicing and Premature Termination of Transcription of the FVIII Gene as a Cause of Severe Canine Hemophilia A: Similarities with the Intron 22 Inversion Mutation in Human Hemophilia

A. Giles, D. Lillicrap, C. Hough, 2002, Thrombosis and Haemostasis.

Home management of haemophilia

S. Israels, D. Lillicrap, M. Poon, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Cell type-specific regulation of von Willebrand factor expression by the E4BP4 transcriptional repressor.

D. Lillicrap, C. Hough, C. Notley, 2005, Blood.

Cell type – specific regulation of von Willebrand factor expression by the E 4 BP 4 transcriptional repressor

D. Lillicrap, C. Hough, C. Notley, 2005 .

Gene Therapy for Coagulation Disorders.

D. Lillicrap, L. Swystun, 2016, Circulation research.

Functional Roles of the von Willebrand Factor Propeptide

D. Lillicrap, O. Rawley, 2021, Hämostaseologie.

Von Willebrand disease.

P. James, D. Lillicrap, J. Robertson, 2008, Pediatric clinics of North America.

The common VWF single nucleotide variants c.2365A>G and c.2385T>C modify VWF biosynthesis and clearance.

D. Hampshire, J. Goudemand, C. Halldén, 2018, Blood advances.

Discrepant platelet and plasma von Willebrand factor in von Willebrand disease patients with p.Pro2808Leufs*24

P. James, D. Lillicrap, A. Tuttle, 2017, Journal of thrombosis and haemostasis : JTH.

The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels.

A. Paterson, R. Montgomery, P. James, 2013, Blood.

Use of a mouse model to elucidate the phenotypic effects of the von Willebrand factor cleavage mutants, Y1605A/M1606A and R1597W

D. Lillicrap, C. Hegadorn, S. Haberichter, 2012, Journal of thrombosis and haemostasis : JTH.

Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance.

Hisham S. Elbatarny, M. Othman, D. Lillicrap, 2007, Blood.

The −1185 A/G and −1051 G/A dimorphisms in the von Willebrand factor gene promoter and risk of myocardial infarction

N. Samani, R. Steeds, D. Lillicrap, 2001, British journal of haematology.

Characterization of viability and proliferation of alginate-poly-L-lysine-alginate encapsulated myoblasts using flow cytometry.

K. Jones, G. Hortelano, D. Lillicrap, 2010, Journal of biomedical materials research. Part B, Applied biomaterials.

ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders

B. Coller, A. Tosetto, P. James, 2010, Journal of thrombosis and haemostasis : JTH.

Gene therapy for hemophilia: an imperative to succeed

D. Lillicrap, C. Hough, D. Lillicrap, 2005, Journal of thrombosis and haemostasis : JTH.

Multiplex analysis of two intragenic microsatellite repeat polymorphisms in the genetic diagnosis of haemophilia A

D. Lillicrap, S. Taylor, S. Windsor, 1994, British journal of haematology.

Haemophilia: strategies for carrier detection and prenatal diagnosis.

K. Nicolaides, P. Mannucci, R. Ljung, 1993, Bulletin of the World Health Organization.

Effect of the Factor V Leiden Mutation on the Clinical Expression of Severe Hemophilia A

B. Ritchie, M. Blajchman, D. Lillicrap, 2000, Thrombosis and Haemostasis.

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice

R. Blumberg, D. Lillicrap, N. Josephson, 2015, Cellular immunology.

Progress in the molecular biology of inherited bleeding disorders

K. High, S. Pipe, D. Lillicrap, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy.

B. Brown, D. Lillicrap, Brian D Brown, 2002, Blood.

Hemophilia Gene Therapy: An Overview

D. Lillicrap, 2014 .

Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response.

M. Ozelo, V. Arruda, A. Winterborn, 2014, Blood.

circulating FVIII antigen and a complex immune response Omental implantation of BOECs in hemophilia dogs results in

M. Ozelo, V. Arruda, A. Winterborn, 2014 .

Chapter 35. Hemophilia Gene Therapy: An Overview

D. Lillicrap, 2010 .

1 THE IMMUNOLOGY OF GENE TRANSFER : AN OVERVIEW

D. Lillicrap, B. Waters, 2008 .

Ex Vivo Gene Therapy for Hemophilia A That Enhances Safe Delivery and Sustained In Vivo Factor VIII Expression from Lentivirally Engineered Endothelial Progenitors

R. Hebbel, B. Brown, J. Galipeau, 2007, Stem cells.

Inducing Tregs with hepatic gene therapy

D. Lillicrap, 2007 .

Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment

T. VandenDriessche, S. Pipe, D. Lillicrap, 2007, Journal of thrombosis and haemostasis : JTH.

Cellular and genetic therapies for haemophilia

K. High, T. VandenDriessche, D. Lillicrap, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.

F. Graham, C. Shi, B. Brown, 2004, Blood.

Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A population

W. Hopman, D. Lillicrap, I. Pabinger, 2020, Journal of thrombosis and haemostasis : JTH.

Genetic determinants of VWF clearance and FVIII-binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.

V. Blanchette, M. Carcao, W. Hopman, 2019, Blood.

Genetic regulation of plasma von Willebrand factor levels in health and disease

D. Lillicrap, L. Swystun, 2018, Journal of thrombosis and haemostasis : JTH.

How much do we really know about von Willebrand disease?

D. Lillicrap, L. Swystun, 2016, Current opinion in hematology.

Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.

D. Bellissimo, R. Hoffmann, C. Leissinger, 2016, Blood.

Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations

J. Sutherland, L. O'Brien, D. Weaver, 2004, Journal of molecular modeling.

Binding of the Ets factor GA-binding protein to an upstream site in the factor IX promoter is a critical event in transactivation

D. Lillicrap, C. Mueller, L. Boccia, 1996, Molecular and cellular biology.

Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis

C. Maas, W. Lam, A. Sood, 2018, Research and practice in thrombosis and haemostasis.

Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire

V. Blanchette, P. James, D. Lillicrap, 2010, Journal of thrombosis and haemostasis : JTH.

A prospective evaluation of the prevalence of symptomatic von Willebrand disease (VWD) in a pediatric primary care population

P. James, W. Hopman, D. Lillicrap, 2010, Pediatric blood & cancer.

Type 1 von Willebrand disease: application of emerging data to clinical practice

D. Lillicrap, P. Collins, A. Cumming, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

dogs with hemophilia A Efficacy and safety of a new-class hemostatic drug candidate, AV513, in

Kirk W. Johnson, D. Lillicrap, A. Labelle, 2013 .

Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A.

Kirk W. Johnson, D. Lillicrap, A. Labelle, 2008, Blood.

Efficacy and Safety of a New-Class of Hemostatic Drug Candidate , AV 513 , in Hemophilia A Dogs

Kirk W. Johnson, D. Lillicrap, A. Labelle, 2007 .

Changes

D. Lillicrap, James H. Morrissey, 2020, Journal of thrombosis and haemostasis : JTH.

Stabilin‐2 deficiency increases thrombotic burden and alters the composition of venous thrombi in a mouse model

D. Lillicrap, C. Notley, L. Swystun, 2021, Journal of thrombosis and haemostasis : JTH.

The scavenger receptor SCARA5 is an endocytic receptor for von Willebrand factor expressed by littoral cells in the human spleen

K. Tryggvason, D. Lillicrap, J. Lai, 2019, Journal of thrombosis and haemostasis : JTH.

Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms

P. James, W. Hopman, D. Lillicrap, 2016, Journal of thrombosis and haemostasis : JTH.

Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

P. Lenting, R. Montgomery, S. Pipe, 2016, Blood.

Third Åland islands conference on von Willebrand disease, 26–28 September 2012: meeting report

V. Jiménez‐Yuste, M. Morfini, M. Makris, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.

D. Lillicrap, 2013, Hematology. American Society of Hematology. Education Program.

von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.

D. Lillicrap, 2013, Blood.

The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study.

L. O'Brien, J. Leggo, M. Othman, 2007, Blood.

Innovative Molecular Testing Strategies for Adjunctive Investigations in Hemostasis and Thrombosis

D. Lillicrap, E. Ghorbanpour, 2019, Seminars in Thrombosis and Hemostasis.

The genetics of venous and arterial thromboembolism

D. Lillicrap, 2001, Current atherosclerosis reports.

Generation and validation of the Condensed MCMDM‐1VWD Bleeding Questionnaire for von Willebrand disease

P. James, W. Hopman, D. Lillicrap, 2008, Journal of thrombosis and haemostasis : JTH.

Molecular Diagnostic Approaches to Hemostasis

P. James, D. Lillicrap, 2007 .

What is a cure and how do we get there?

M. Ozelo, D. Lillicrap, G. Pierce, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A

V. Blanchette, M. Carcao, J. Leggo, 2003, Journal of thrombosis and haemostasis : JTH.

The molecular pathology of hemophilia A.

D. Lillicrap, 1991, Transfusion medicine reviews.

Scientific method and the COVID pandemic

D. Lillicrap, J. Morrissey, 2022, Journal of Thrombosis and Haemostasis.

Biological considerations of plasma-derived and recombinant factor VIII immunogenicity.

J. Tarrant, D. Lillicrap, J. Lai, 2017, Blood.

To clear or to fear: An innate perspective on factor VIII immunity

D. Lillicrap, J. Lai, C. Hough, 2015, Cellular Immunology.

Variability of thromboelastographic responses following the administration of rFVIIa to haemophilia A dogs supports the individualization of therapy with a global test of haemostasis

M. Othman, W. Hopman, D. Lillicrap, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations

E. Neufeld, A. Iorio, J. Blatny, 2018, Research and practice in thrombosis and haemostasis.

Minimal dataset for post‐registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH

A. Iorio, F. Rosendaal, M. Makris, 2017, Journal of thrombosis and haemostasis : JTH.

Multicentric warfarin‐induced skin necrosis complicating heparin‐induced thrombocytopenia

W. Sikov, D. Lillicrap, T. Warkentin, 1999, American journal of hematology.

Translational medicine advances in von Willebrand disease

D. Lillicrap, 2013, Journal of thrombosis and haemostasis : JTH.

Role of von Willebrand factor in venous thromboembolic disease

D. Lillicrap, A. Michels, Michael Yacob, 2021, JVS-vascular science.

Comprehensive analysis of the role of von Willebrand factor and platelet glycoprotein VI-and α 2 β 1-mediated collagen binding in thrombus formation

B. Nieswandt, D. Lillicrap, Kate Sponagle, 2014 .

THROMBOSIS AND HEMOSTASIS Analysis of the role of von Willebrand factor , platelet glycoprotein VI-, and a 2 b 1-mediated collagen binding in thrombus formation

B. Nieswandt, D. Lillicrap, Kate Sponagle, 2014 .

von Willebrand's disease: a report from a meeting in the Åland islands

M. Laffan, R. Montgomery, A. Federici, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical, Laboratory, and Molecular Markers of Type 1 von Willebrand Disease

F. Rodeghiero, D. Lillicrap, I. Peake, 2011 .

von Willebrand disease: laboratory aspects of diagnosis and treatment

D. Lillicrap, E. Favaloro, C. Mazurier, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy and Safety of the Factor VIII/von Willebrand Factor Concentrate, Haemate-P/Humate-P: Ristocetin Cofactor Unit Dosing in Patients with von Willebrand Disease

D. Lillicrap, M. Poon, I. Walker, 2002, Thrombosis and Haemostasis.

Recombinant Factor IX Recovery and Inhibitor Safety: A Canadian Post-licensure Surveillance Study

D. Lillicrap, M. Poon, R. Card, 2002, Thrombosis and Haemostasis.

von Willebrand Disease in a Pediatric-based Population - Comparison of Type 1 Diagnostic Criteria and Use of the PFA-100® and a von Willebrand Factor/Collagen-binding Assay

V. Blanchette, M. Carcao, D. Lillicrap, 2000, Thrombosis and Haemostasis.

Porcine recombinant factor VIII (Obizur; OBI‐1; BAX801): product characteristics and preclinical profile

F. Horling, D. Lillicrap, P. Lollar, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Lymphoproliferative disease of 'lak cell' precursor large granular lymphocytes in association with celiac disease

D. Lillicrap, H. Pross, P. Galbraith, 1993, American journal of hematology.

Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.

S. Kochanek, B. Brown, N. Van Rooijen, 2003, Blood.

Histones link inflammation and thrombosis through the induction of Weibel–Palade body exocytosis

P. Liaw, P. James, D. Lillicrap, 2016, Journal of thrombosis and haemostasis : JTH.

In vitro and in vivo evaluation of the effect of elevated factor VIII on the thrombogenic process

D. Lillicrap, J. Mewburn, M. Golder, 2012, Thrombosis and Haemostasis.

The Canine Factor VIII cDNA and 5’ Flanking Sequence

A. Giles, D. Lillicrap, C. Hough, 1998, Thrombosis and Haemostasis.

Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs.

M. Kaleko, S. Connelly, D. Lillicrap, 2001, Blood.

War and peace: Factor VIII and the adaptive immune response.

D. Lillicrap, J. Lai, C. Hough, 2016, Cellular immunology.

Reduction of the immune response to factor VIII mediated through tolerogenic factor VIII presentation by immature dendritic cells

M. Ozelo, M. Othman, D. Lillicrap, 2008, Journal of thrombosis and haemostasis : JTH.

Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice

D. Lillicrap, J. Mewburn, C. Notley, 2017, Journal of thrombosis and haemostasis : JTH.

Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response.

P. Thompson, D. Lillicrap, C. Hough, 2009, Blood.

A Novel Cell-Sheet Technology That Achieves Durable Factor VIII Delivery in a Mouse Model of Hemophilia A

T. Okano, K. Ohashi, D. Lillicrap, 2013, PloS one.

Role of the liver-enriched transcription factor hepatocyte nuclear factor 1 in transcriptional regulation of the factor V111 gene

D. Lillicrap, C. Mueller, C. Notley, 1996, Molecular and cellular biology.

Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report

P. Noris, A. Srivastava, V. Blanchette, 2019, HemaSphere.

cytokine production to favor a Th1 response by a regulatory CD4+CD25+-dependent mechanism and by shifting Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice

D. Lillicrap, C. Hough, A. Labelle, 2013 .

A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells.

B. Brown, C. Miao, T. VandenDriessche, 2009, Blood.

Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4 (cid:1) CD25 (cid:1) -dependent mechanism and by shifting cytokine production to favor a Th1 response

P. Thompson, D. Lillicrap, C. Hough, 2008 .

cytokine production to favor a Th 1 response-dependent mechanism and by shifting + CD 25 + by a regulatory CD 4 Anti-CD 3 prevents factor VIII inhibitor development in hemophilia A mice

P. Thompson, D. Lillicrap, C. Hough, 2008 .

Endothelial characteristics in healthy endothelial colony forming cells; generating a robust and valid ex vivo model for vascular disease

E. Weijers, J. Eikenboom, P. James, 2020, Journal of thrombosis and haemostasis : JTH.

Enhanced binding of HLF/DBP heterodimers represents one mechanism of PAR protein transactivation of the factor VIII and factor IX genes.

D. Lillicrap, C. Mueller, M. Begbie, 1999, DNA and cell biology.

The molecular basis of haemophilia B

C. Kessler, D. Lillicrap, U. Martinowitz, 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

Androgen effects on factor IX expression: in‐vitro and in‐vivo studies in mice

D. Lillicrap, C. Cameron, C. Notley, 1998, British journal of haematology.

An A to T transversion at position -5 of the factor IX promoter results in hemophilia B.

D. Lillicrap, P. Bridge, D. Picketts, 1992, Genomics.

The diagnosis and management of von Willebrand disease in Canada.

P. James, D. Lillicrap, 2011, Seminars in thrombosis and hemostasis.

Frequency of Platelet type versus Type 2B von Willebrand Disease

M. Ozelo, J. Leggo, M. Othman, 2011, Thrombosis and Haemostasis.

Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors.

J. Astermark, Christine A. Lee, D. Lillicrap, 2006, Seminars in thrombosis and hemostasis.

Alternative therapies for the management of inhibitors

D. Lillicrap, M. Shima, R. Kruse-Jarres, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Platelet type von Willebrand disease and registry report: communication from the SSC of the ISTH

M. Othman, J. Di Paola, P. Gresele, 2016, Journal of thrombosis and haemostasis : JTH.

Recommendations for performing thromboelastography/thromboelastometry in hemophilia: communication from the SSC of the ISTH

D. Lillicrap, G. Young, G. Rivard, 2014, Journal of thrombosis and haemostasis : JTH.

The role of molecular genetics in diagnosing von Willebrand disease.

P. James, D. Lillicrap, 2008, Seminars in thrombosis and hemostasis.

The Factor VIII Acute Phase Response Requires the Participation of NFκB and C/EBP

D. Lillicrap, S. Tinlin, C. Notley, 2000, Thrombosis and Haemostasis.

Quantification of perioperative changes in von Willebrand factor and factor VIII during elective orthopaedic surgery in normal individuals

W. Hopman, D. Lillicrap, A. Tuttle, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

The Jamaican Haemophilia Registry: Describing the burden of disease

V. Blanchette, N. Young, A. Abad, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Treatment of hemophilia: recombinant clotting factors

V. Blanchette, D. Lillicrap, C. Sabapathy, 2014 .

Animal models of inhibitors

V. Arruda, D. Lillicrap, B. Reipert, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Germ-line mosaicism for a valine-to-methionine substitution at residue 553 in the glycoprotein Ib-binding domain of von Willebrand factor, causing type IIB von Willebrand disease.

A. Giles, D. Lillicrap, E. W. Murray, 1992, American journal of human genetics.

N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice

J. Dennis, D. Lillicrap, J. Lai, 2018, Haematologica.

Hemophilia Gene Therapy: Approaching the First Licensed Product

P. Batty, D. Lillicrap, 2021, HemaSphere.

Hemophilia gene therapy knowledge and perceptions: Results of an international survey

A. Srivastava, K. Pasi, J. Mahlangu, 2020, Research and practice in thrombosis and haemostasis.

Observation of superconductivity in the organometallic intercalation compound SnSe2{Co(η-C5H5)2}0.33

P. A. Cox, D. O′Hare, D. Lillicrap, 1990 .

Thrombotic endocarditis and lupus anticoagulant. A pathogenetic possibility for idiopathic 'rheumatic type' valvular heart disease.

D. Lillicrap, D. Brunet, P. Ford, 1989, Archives of pathology & laboratory medicine.

Absence of allelic loss on chromosome 5q by RFLP analysis in preleukemia.

D. Lillicrap, C. Cameron, S. Windsor, 1991, Leukemia research.

Testing novel hemophilia therapies: of mice and men

D. Lillicrap, 2004 .

Recombination between the factor VIII gene and the DXS52 locus gives the most probable genetic order as centromere-fra(X)-DXS15-DXS52-F8C-telomere.

L. Mulligan, A. Giles, B. White, 1987, American journal of medical genetics.

Carrier detection of haemophilia A using DNA markers in families with an isolated affected male

A. Giles, B. White, J. Teitel, 1987, Clinical genetics.

Association of lupus anticoagulant with severe valvular heart disease in systemic lupus erythematosus.

D. Lillicrap, P. Ford, F. Se, 1988, The Journal of rheumatology.

Positive immunoglobulin gene rearrangement study by the polymerase chain reaction in a colonic adenocarcinoma.

D. Lillicrap, F. Ling, C. Clarke, 1992, American journal of clinical pathology.

Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector.

A. Parker, J. F. Wright, L. Couto, 2003, Blood.

Sensitivity of PCR in detecting monoclonal B cell proliferations.

D. Lillicrap, F. Ling, W. Corbett, 1993, Journal of clinical pathology.

Risk of venous thromboembolism associated with the common hereditary haemochromatosis Hfe gene (C282Y) mutation

T. Baglin, D. Lillicrap, S. Taylor, 1999, British journal of haematology.

Heterogeneity of laboratory test results for antiphospholipid antibodies in patients treated with chlorpromazine and other phenothiazines.

M. Pinto, D. Lillicrap, P. Ford, 1990, American journal of clinical pathology.

Immunoglobulin isotypes and functional anti‐FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice

M. Othman, D. Lillicrap, C. Hough, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

The genetics of Canadian type 3 von Willebrand disease: further evidence for co‐dominant inheritance of mutant alleles

V. Blanchette, J. Leggo, P. James, 2013, Journal of thrombosis and haemostasis : JTH.

Challenges in defining type 2M von Willebrand disease: results from a Canadian cohort study

P. James, D. Lillicrap, M. Poon, 2007, Journal of thrombosis and haemostasis : JTH.

The value of genetic testing for type 2B Von Willebrand disease.

P. James, D. Lillicrap, D. Rapson, 2006, Clinical and laboratory haematology.

Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease.

J. Sutherland, L. O'Brien, M. Othman, 2003, Blood.

Gonadal mosaicism in a family with adrenoleukodystrophy: Molecular diagnosis of carrier status among daughters of a gonadal mosaic when direct detection of the mutation is not possible

D. Lillicrap, P. Macleod, P. Bridge, 1992, Journal of Inherited Metabolic Disease.

Current status of haemophilia gene therapy

D. Lillicrap, A. Nathwani, T. Spencer, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

The Canadian “National Program for hemophilia mutation testing” database: A ten‐year review

J. Leggo, P. James, D. Lillicrap, 2013, American journal of hematology.

Absence of overt iron overload in two individuals compound heterozygotes for a 22 base pair deletion of exon 2 and the C282Y missense mutation of the HFE gene

M. E. Aubrey, D. Lillicrap, S. Taylor, 2003, Clinical genetics.

An association between the common hereditary hemochromatosis mutation and the factor V Leiden allele in a population with thrombosis.

D. Lillicrap, S. Taylor, Y. G. Xie, 1998, Blood.

Haemophilia B: database of point mutations and short additions and deletions, fifth edition, 1994.

P. Reitsma, R. Schwaab, G. Brownlee, 1994, Nucleic acids research.

Premature stroke in a family with lupus anticoagulant and antiphospholipid antibodies.

D. Lillicrap, D. Brunet, P. Ford, 1990, Stroke.

Absence of a bleeding tendency in severe acquired von Willebrand's disease. The role of platelet von Willebrand factor in maintaining normal hemostasis.

A. Giles, D. Lillicrap, J. Drouin, 1989, American journal of clinical pathology.

Multimerin 1 supports platelet function in vivo and binds to specific GPAGPOGPX motifs in fibrillar collagens that enhance platelet adhesion

B. Doble, H. Ni, D. Lillicrap, 2020, Journal of thrombosis and haemostasis : JTH.

The role of immunomodulation in the management of factor VIII inhibitors.

D. Lillicrap, 2006, Hematology. American Society of Hematology. Education Program.

Factors influencing therapeutic efficacy and the host immune response to helper‐dependent adenoviral gene therapy in hemophilia A mice

F. Graham, C. Shi, B. Brown, 2004, Journal of thrombosis and haemostasis : JTH.

Prolonged thrombocytopenia in post‐transfusion purpura (PTP) associated with changes in the crossed immunoelectrophoretic pattern of von Willebrand factor (vWF), circulating immune complexes and endothelial cell cytotoxicity

A. Giles, D. Lillicrap, P. Ford, 1986, British journal of haematology.

Heterogeneity and reciprocity of FVIII and VWF expression, and the response to shear stress in cultured human endothelial cells

D. Lillicrap, C. Hough, C. Notley, 2022, Journal of thrombosis and haemostasis : JTH.

Extending half-life in coagulation factors: where do we stand?

D. Lillicrap, 2008, Thrombosis research.

Gene therapy for hemophilia: Current status and laboratory consequences

P. Batty, D. Lillicrap, 2021, International journal of laboratory hematology.

Functional characterisation of the type 1 von Willebrand disease candidate VWF gene variants: p.M771I, p.L881R and p.P1413L.

D. Lillicrap, Z. Başlar, M. Ozbil, 2017, Blood transfusion = Trasfusione del sangue.

Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease.

D. Hampshire, M. Othman, A. Parker, 2010, Blood.

Analysis of the role of von Willebrand factor, platelet glycoprotein VI-, and α2β1-mediated collagen binding in thrombus formation.

B. Nieswandt, D. Lillicrap, Kate Sponagle, 2014, Blood.

Application of in-vitro-cultured primary hepatocytes to evaluate species translatability and AAV transduction mechanisms of action

S. Bunting, S. Fong, G. Berguig, 2022, Molecular therapy. Methods & clinical development.

The effect of exercise on von Willebrand factor and ADAMTS‐13 in individuals with type 1 and type 2B von Willebrand disease

P. Lenting, P. James, D. Lillicrap, 2007, Journal of thrombosis and haemostasis : JTH.

Early cellular interactions and immune transcriptome profiles in human factor VIII‐exposed hemophilia A mice

J. Voorberg, A. V. van Velzen, D. Lillicrap, 2018, Journal of thrombosis and haemostasis : JTH.

Evaluating the potential benefits of the extravascular pool of factor IX

D. Lillicrap, 2020, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

The prevalence of symptomatic von Willebrand disease in primary care practice

P. James, W. Hopman, D. Lillicrap, 2010, Journal of thrombosis and haemostasis : JTH.

Ethical issues in haemophilia

A. Chuansumrit, J. Kimmelman, A. Thompson, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Fifty years new

D. Lillicrap, J. Morrissey, 2018, Journal of thrombosis and haemostasis : JTH.

Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease

P. James, D. Lillicrap, J. Grabell, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

To clot or not to clot? Ad is the question—Insights on mechanisms related to vaccine‐induced thrombotic thrombocytopenia

M. Othman, A. Parker, D. Lillicrap, 2021, Journal of Thrombosis and Haemostasis.

ADAMTS13 cleavage efficiency is altered by mutagenic and, to a lesser extent, polymorphic sequence changes in the A1 and A2 domains of von Willebrand factor

L. O'Brien, D. Lillicrap, C. Notley, 2008, British journal of haematology.

First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System

A. Iorio, N. Heddle, B. Ritchie, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor

P. Mannucci, J. Eikenboom, R. Montgomery, 2006, Journal of thrombosis and haemostasis : JTH.

The future of hemostasis management

D. Lillicrap, 2013, Pediatric blood & cancer.

Improvements in factor concentrates

D. Lillicrap, 2010, Current opinion in hematology.

Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study

P. Babyn, S. Israels, V. Blanchette, 2006, Journal of thrombosis and haemostasis : JTH.

Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care

M. Carcao, D. Lillicrap, G. Rivard, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

von Willebrand disease update: diagnostic and treatment dilemmas

J. Goudemand, D. Lillicrap, E. Berntorp, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Aminoglycoside suppression of nonsense mutations in severe hemophilia.

J. Leggo, P. James, D. Lillicrap, 2005, Blood.

Challenges and innovations in the treatment of bleeding disorders.

D. Lillicrap, J. Dipaola, 2011, Thrombosis research.

Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms

K. Fijnvandraat, D. Lillicrap, M. Mancuso, 2020, Expert review of hematology.

Haemophilia gene therapy: the patients’ perspective

B. Knoppers, D. Lillicrap, R. Isasi, 2009, Haemophilia.

Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels

J. Dumont, I. Nestorov, D. Quon, 2014, Journal of thrombosis and haemostasis : JTH.

Pharmacokinetics of recombinant factor VIII (Kogenate‐FS®) in children and causes of inter‐patient pharmacokinetic variability

V. Blanchette, M. Carcao, D. Lillicrap, 2006 .

Novel and Clinically Significant Factors Influencing the Pharmacokinetic Variability of Recombinant Factor VIII (Kogenate-FS) in Children.

V. Blanchette, M. Carcao, D. Lillicrap, 2004 .

International comparative field study of N8 evaluating factor VIII assay performance

D. Viuff, D. Lillicrap, T. Barrowcliffe, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

A complete deletion of the factor IX gene and new TaqI variant in a hemophilia B kindred

A. Giles, B. White, D. Lillicrap, 1988, Human Genetics.

Comparative pharmacokinetics of two extended half‐life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?

A. Iorio, M. Morfini, V. Blanchette, 2019, Journal of thrombosis and haemostasis : JTH.

Report of a joint WHO/WFH meeting on the control of haemophilia: carrier detection and prenatal diagnosis.

K. Nicolaides, P. Mannucci, R. Ljung, 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Factor VIII gene inversions in severe hemophilia A: results of an international consortium study.

F E Preston, P G Mori, S S Sommer, 1995, Blood.

von Willebrand disease: pathogenesis, classification, and management.

D. Lillicrap, E. W. Murray, 1996, Transfusion medicine reviews.

Dexamethasone promotes durable factor VIII-specific tolerance in hemophilia A mice via thymic mechanisms

P. Moorehead, A. V. van Velzen, D. Lillicrap, 2018, Haematologica.

Theories of Blood Coagulation

Bradley E Aouizerat, Christine Miaskowski, C. Miaskowski, 2007, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses.

A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects

J. Blatny, M. Morfini, V. Blanchette, 2021, Thrombosis and Haemostasis.

More on: are randomized clinical trials the only truth? Not always

P. Mannucci, C. Kessler, P. Monahan, 2006, Journal of thrombosis and haemostasis : JTH.

Endogenous factor VIII synthesis from the intron 22–inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A

C. Yanover, T. Przytycka, S. Cole, 2013, Nature Medicine.

Title Endogenous factor VIII synthesis from the intron 22-inverted F 8 locus may modulate the immunogenicity of replacement therapy for hemophilia

Yasmin, C. Yanover, T. Przytycka, 2014 .

The improved factor concentrate

D. Lillicrap, 2009, Hämostaseologie.

Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.

L. Couto, C. Scallan, Shangzhen Zhou, 2006, Blood.

Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table

A. Weill, T. Sannié, K. Pasi, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Advances and Challenges for Hemophilia Gene Therapy.

P. Batty, D. Lillicrap, 2019, Human molecular genetics.

Different clinical phenotype in triplets with haemophilia A

M. Carcao, J. Leggo, D. Lillicrap, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

The canine factor VIII 3'-untranslated region and a concatemeric hepatocyte nuclear factor 1 regulatory element enhance factor VIII transgene expression in vivo.

D. Lillicrap, C. Hough, A. Killoran, 2002, Human gene therapy.

The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates

A. Giles, S. Israels, V. Blanchette, 1995, Transfusion.

In vitro and in vivo stability of diluted recombinant factor VIII for continuous infusion use in haemophilia A

V. Blanchette, S. Revel-Vilk, D. Lillicrap, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Future prospects for the treatment of hemophilia: A global perspective

D. Lillicrap, 2018, HemaSphere.

New Advances in the Treatment of Children with Hemophilia

D. Lillicrap, 2014 .

The World Federation of Hemophilia and research

D. Lillicrap, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.

H. Kazazian, M. Ozelo, T. Nichols, 2010, Blood.

Bleeding disorders, menorrhagia and iron deficiency: impacts on health‐related quality of life

J. Horsman, W. Furlong, C. Rae, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian Type 1 VWD Study

A. Paterson, L. O'Brien, J. Leggo, 2006, Journal of thrombosis and haemostasis : JTH.

The molecular mechanisms of immunomodulation and tolerance induction to factor VIII

D. Lillicrap, B Waters, D Lillicrap, 2009, Journal of thrombosis and haemostasis : JTH.

Reliability and Reproducibility of Classification of Children as “Bleeders” Versus “Non-Bleeders” Using a Questionnaire for Significant Mucocutaneous Bleeding

V. Blanchette, S. Revel-Vilk, D. Lillicrap, 2004, Journal of pediatric hematology/oncology.

Hierarchical scaffold design for mesenchymal stem cell-based gene therapy of hemophilia B.

A. Yousefi, M. Blostein, Rouwayda El Ayoubi, 2011, Biomaterials.

Efficient Lentiviral Transduction and Improved Engraftment of Human Bone Marrow Mesenchymal Cells

H. Vandenburgh, F. Luyten, F. Dell’Accio, 2006, Stem cells.

A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A.

L. Naldini, M. Ozelo, B. Brown, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.

M. Othman, D. Lillicrap, C. Hough, 2009, Blood.

Factor VIII inhibitors: Advances in basic and translational science

D. Lillicrap, J. Lai, 2017, International journal of laboratory hematology.

A 4% Solution of Bovine Serum Albumin May Be Used in Place of Factor VIII:C Deficient Plasma in the Control Sample in the Nijmegen Modification of the Bethesda Factor VIII:C Inhibitor Assay

A. Giles, W. V. van Heerde, B. Verbruggen, 2002, Thrombosis and Haemostasis.

Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysis

J. Voorberg, M. Carcao, K. Fischer, 2022, Research and practice in thrombosis and haemostasis.

Gut dysbiosis modulates the immune response to factor VIII in murine hemophilia A.

M. Cormier, J. Tarrant, D. Lillicrap, 2020, Blood advances.

Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcγRIIB Receptor

D. Scott, J. Dumont, P. Moorehead, 2020, Frontiers in Immunology.

Tolerating Factor VIII: Recent Progress

D. Scott, S. Lacroix-Desmazes, J. Voorberg, 2020, Frontiers in Immunology.

A complex substitute: antibody therapy for hemophilia

D. Lillicrap, 2012, Nature Medicine.

A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose

M. Carcao, D. Lillicrap, G. Rivard, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Thromboelastography reflects global hemostatic variation among severe haemophilia A dogs at rest and following acute exercise

M. Othman, W. Hopman, D. Lillicrap, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Non‐neutralizing anti‐FVIII antibodies: different binding specificity to different recombinant FVIII concentrates

D. Lillicrap, G. Rivard, C. Meilleur, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Canine models of inherited bleeding disorders in the development of coagulation assays, novel protein replacement and gene therapies

T. Nichols, D. Lillicrap, C. Hough, 2016, Journal of thrombosis and haemostasis : JTH.

biphasic liver toxicity in hemophilia A dogs results in short-term phenotypic correction, inhibitor development, and Systemic delivery of an adenoviral vector encoding canine factor VIII

M. Kaleko, S. Connelly, D. Lillicrap, 2013 .

In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice.

D. Kayda, M. Kaleko, S. Connelly, 1999, Human gene therapy.

Summary report of the First International Conference on inhibitors in haemophilia A.

L. Mantovani, P. Mannucci, F. Rosendaal, 2017, Blood transfusion = Trasfusione del sangue.

von Willebrand Disease: a Report from a Meeting in the Åland Islands 2012 Summary of a Nordic Symposium on von Willebrand Disease, 26–28 September 2012, Mariehamn, Åland, Finland

V. Jiménez‐Yuste, M. Morfini, M. Makris, 2013 .

Alloantibodies in von Willebrand disease.

P. Mannucci, P. James, D. Lillicrap, 2013, Blood.

Genetically-Engineered Endothelial Cells Implanted Into the Omentum of Hemophilia A Dogs Provides Long-Term Circulating FVIII Resulting From Sustained FVIII Expression and Persistent Cell Viability.

M. Ozelo, J. Hulvat, A. Winterborn, 2009 .

Molecular diagnosis of inherited bleeding disorders and thrombophilia.

D. Lillicrap, 1999, Seminars in hematology.

Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice.

H. Ochs, R. Kaufman, D. Rawlings, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Solulin increases clot stability in whole blood from humans and dogs with hemophilia.

D. Lillicrap, B. Sørensen, J. Foley, 2012, Blood.

Site-Specific PEGylation of Factor VIII (PEG-FVIII) Preserves Full Clotting Activity and Extends Therapeutic Efficacy in HemophiliaA Dogs

John E. Murphy, D. Lillicrap, A. Labelle, 2008 .

Molecular coevolution of coagulation factor VIII and von Willebrand factor.

E. Gaucher, H. Spencer, C. Doering, 2021, Blood advances.

FVIII stabilization: VWF D'D3 will do.

D. Lillicrap, L. Swystun, 2014, Blood.

Comment on Yee et al , page 445 FVIII stabilization : VWF D 9 D 3 will do

D. Lillicrap, 2014 .

Haemophilia B: database of point mutations and short additions and deletions--second edition.

P. Reitsma, K. High, D. Lillicrap, 1991, Nucleic acids research.

Carrier detection strategy in haemophilia A: the benefits of combined DNA marker analysis and coagulation testing in sporadic haemophilic families

A. Giles, B. White, D. Lillicrap, 1988, British journal of haematology.

LINKED AND INTRAGENIC PROBES FOR HAEMOPHILIA A

A. Bloom, D. Lillicrap, I. Peake, 1985, The Lancet.

Carrier detection in the hemophilias

A. Giles, B. White, D. Lillicrap, 1987, American journal of hematology.

Genetic sequence analysis of inherited bleeding diseases.

F. Peyvandi, D. Lillicrap, T. Kunicki, 2013, Blood.

Shear stress and platelet‐induced tensile forces regulate ADAMTS13‐localization within the platelet thrombus

D. Lillicrap, C. Hough, J. Mewburn, 2019, Research and practice in thrombosis and haemostasis.

Somatic mosaicism and female-to-female transmission in a kindred with hemophilia B (factor IX deficiency).

D. Lillicrap, S. Taylor, K. Deugau, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Hemophilia gene therapy: it's a matter of expression

D. Lillicrap, 2004 .

Hemophilia treatment. Gene therapy, factor VIII antibodies and immune tolerance: hopes and concerns.

D. Lillicrap, 2000, Haematologica.

World bleeding disorders registry: The pilot study

A. Iorio, D. Lillicrap, H. M. van den Berg, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Genotype/phenotype association in von Willebrand disease: is the glass half full or empty?

D. Lillicrap, 2009, Journal of thrombosis and haemostasis : JTH.

Utility of factor VIII and factor VIII to von Willebrand factor ratio in identifying 277 unselected carriers of hemophilia A

V. Blanchette, M. Carcao, V. Bouskill, 2017, American journal of hematology.

The genetics of Canadian type 3 von Willebrand disease: further evidence for codominant inheritance of mutant alleles: a reply to a rebuttal

P. James, D. Lillicrap, M. Bowman, 2013, Journal of thrombosis and haemostasis : JTH.

The molecular characterization of von Willebrand disease: good in parts

P. James, D. Lillicrap, David Lillicrap, 2013, British journal of haematology.

Von Willebrand Disease: Basic and Clinical Aspects

Christine A. Lee, R. Montgomery, A. Federici, 2011 .

VON WILLEBRAND DISEASE: AN INTRODUCTION FOR THE PRIMARY CARE PHYSICIAN

P. James, D. Lillicrap, 2009 .

Von Willebrand disease - phenotype versus genotype: deficiency versus disease.

D. Lillicrap, David Lillicrap, 2007, Thrombosis research.

An assessment of the pathogenic significance of the R924Q von Willebrand factor substitution

P. James, D. Lillicrap, C. Hough, 2009, Journal of thrombosis and haemostasis : JTH.

von Willebrand disease: Clinical and laboratory lessons learned from the large von Willebrand disease studies

P. James, D. Lillicrap, 2012, American journal of hematology.

Common VWF Haplotypes in Normal African-Americans and Caucasians Recruited into the ZPMCB-VWD and Their Impact on VWF Laboratory Testing.

D. Bellissimo, C. Leissinger, R. Montgomery, 2007 .

Therapeutic consequences for misdiagnosis of Type 2N von Willebrand disease

M. Carcao, Madhu Gupta, K. Friedman, 2011, Pediatric blood & cancer.

Genetic testing for von Willebrand disease: the Canadian experience.

P. James, D. Lillicrap, 2006, Seminars in thrombosis and hemostasis.

Multi-year Therapeutic Benefit of AAV Serotypes 2, 6 and 8 Delivering Factor VIII to Hemophilia A Mice and Dogs Running Title: Long Term Liver-specific AAV-FVIII Therapy in Dogs

Morag, L. Couto, C. Scallan, 2006 .

Heterogeneity of the immune response to adenovirus‐mediated factor VIII gene therapy in different inbred hemophilic mouse strains

F. Graham, B. Brown, D. Lillicrap, 2004, The journal of gene medicine.

Characterization of the Original Christmas Disease Mutation (Cysteine 206 → Serine): From Clinical Recognition to Molecular Pathogenesis

J. Teitel, D. Lillicrap, B. Garvey, 1992, Thrombosis and Haemostasis.

Severe haemophilia A in a female resulting from two de novo factor VIII mutations

E. Neufeld, D. Lillicrap, B. Ewenstein, 1995, British journal of haematology.

Haemophilia B: database of point mutations and short additions and deletions--third edition, 1992.

P. Reitsma, K. High, D. Lillicrap, 1992, Nucleic acids research.

Bispecific Antibody Therapy in Hemophilia.

D. Lillicrap, 2017, The New England journal of medicine.

The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF‐dependent and independent manner

P. James, D. Lillicrap, J. Lai, 2019, Journal of thrombosis and haemostasis : JTH.

Preclinical animal models for hemophilia gene therapy: predictive value and limitations.

D. Lillicrap, F. E. Rawle, 2004, Seminars in thrombosis and hemostasis.

Variation of the non-factor VIII sequences detected by a probe from intron 22 of the factor VIII gene.

D. Lillicrap, S. Taylor, P. Bridge, 1990, Blood.

Molecular testing for disorders of hemostasis

D. Lillicrap, 2013, International journal of laboratory hematology.

Transgene-host cell interactions mediate significant influences on the production, stability, and function of recombinant canine FVIII

M. Ozelo, D. Lillicrap, C. Hough, 2015, Molecular therapy. Methods & clinical development.

Recurring mutations at CpG dinucleotides in the region of the von Willebrand factor gene encoding the glycoprotein Ib binding domain, in patients with type IIB von Willebrand's disease

A. Giles, V. Blanchette, D. Lillicrap, 1991, British Journal of Haematology.

Cosegregation of von Willebrand factor gene polymorphisms and possible germinal mosaicism in type IIB von Willebrand disease.

A. Giles, D. Lillicrap, I. Peake, 1991, Blood.

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial

Marcelo A. Falappa, Tariq M. Alhawassi, A. Laupacis, 2021, BMJ.

Defective propeptide processing and abnormal activation underlie the molecular pathology of factor IX Troed‐y‐Rhiw

D. Lillicrap, I. Peake, M. Liddell, 1989, British journal of haematology.

GENOME SEQUENCING AND ITS IMPACT ON HEMATOLOGY Genetic sequence analysis of inherited bleeding diseases

F. Peyvandi, D. Lillicrap, T. Kunicki, 2013 .

Rapid genotype analysis in type 2B von Willebrand's disease using a universal heteroduplex generator

J. Bidwell, D. Lillicrap, I. Peake, 1995, British journal of haematology.

A novel type 2A (Group II) von Willebrand disease mutation (L1503Q) associated with loss of the highest molecular weight von Willebrand factor multimers

J. Sutherland, L. O'Brien, D. Lillicrap, 2004, Journal of thrombosis and haemostasis : JTH.

Comparison of phenotypic assessment and the use of two restriction fragment length polymorphisms in the diagnosis of the carrier state in haemophilia B

D. Lillicrap, I. Peake, M. Liddell, 1986, British journal of haematology.

A past mutation at Isoleucine397 is now a common cause of moderate/mild haemophilia B

D. Koeberl, A. Shapiro, D. Lillicrap, 1990, British journal of haematology.

Genetic basis of familial Meniere's disease.

K. Fung, Sherryl A. M. Taylor, S. Hall, 2002, The Journal of otolaryngology.

FIX It in One Go: Enhanced Factor IX Gene Therapy for Hemophilia B

D. Lillicrap, 2017, Cell.

Correction of the bleeding time in von Willebrand factor (VWF)-deficient mice using murine VWF.

P. D. de Groot, P. Lenting, C. Denis, 2007, Blood.

Inherited thrombocytopenia, elevated serum IgA and renal disease: identification as a variant of the Wiskott-Aldrich syndrome.

D. Lillicrap, G. Standen, N. Matthews, 1986, The Quarterly journal of medicine.

A novel type 2A von Willebrand factor mutation located at the last nucleotide of exon 26 (3538G>A) causes skipping of 2 nonadjacent exons.

L. O'Brien, P. James, D. Lillicrap, 2004, Blood.

Influence of a GT repeat element on shear stress responsiveness of the VWF gene promoter

L. O'Brien, D. Lillicrap, C. Hough, 2008, Journal of thrombosis and haemostasis : JTH.

A case of non‐resolving hemophilia B Leyden in a 42‐year‐old male (F9 promoter + 13 A>G)

J. Leggo, D. Lillicrap, I. Walker, 2008, Journal of thrombosis and haemostasis : JTH.

Introduction to a series of reviews on cancer-associated thrombotic disease.

D. Lillicrap, 2013, Blood.

Lupus Anticoagulant, Antiphospholipid Antibodies and Migraine

D. Lillicrap, D. Brunet, P. Ford, 1988, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Distinguishing between non‐identical twins: platelet type and type 2B von Willebrand disease

M. Othman, D. Lillicrap, 2007, British journal of haematology.

A single nucleotide polymorphism at nucleotide −1793 in the von Willebrand factor (VWF) regulatory region is associated with plasma VWF:Ag levels

P. Harvey, D. Lillicrap, C. Cameron, 2000, British journal of haematology.

Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF :Ag levels : Identification of three novel single nucleotide polymorphisms in the vWF gene promoter

D. Lillicrap, C. Cameron, A. Keightley, 1999 .

Suppression of anti-drug antibody formation against coagulation factor VIII by oral delivery of anti-CD3 monoclonal antibody in hemophilia A mice.

H. Daniell, R. Herzog, D. Lillicrap, 2023, Cellular immunology.

PREVALENCE OF FACTOR V LEIDEN AND ACTIVATED PROTEIN C RESISTANCE IN CENTRAL RETINAL VEIN OCCLUSION

W. Hodge, D. Lillicrap, S. Taylor, 2001, Retina.

Functional analysis of three recombinant A1-VWF domain mutants in comparison to wild type and plasma-derived VWF facilitates subtyping in type 2 von Willebrand disease.

M. Othman, D. Lillicrap, E. Favaloro, 2011, Thrombosis research.

CANADIAN ASSOCIATION OF NURSES IN HEMOPHILIA CARE The Canadian Association of Nurses in Hemophilia Care

P. James, D. Lillicrap, 2011 .

Mutation-specific hemostatic variability in mice expressing common type 2B von Willebrand disease substitutions.

D. Lillicrap, Kate Sponagle, J. Mewburn, 2010, Blood.

Randomized trials of therapeutic heparin for COVID‐19: A meta‐analysis

K. Thorpe, S. Middeldorp, B. D. da Costa, 2021, Research and Practice in Thrombosis and Haemostasis.

Heparin for Moderately Ill Patients with Covid-19

M. Cushman, K. Thorpe, S. Middeldorp, 2021, medRxiv.

Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter.

D. Lillicrap, C. Cameron, A. Keightley, 1999, Blood.

Disseminated intravascular coagulation in patients with 2019‐nCoV pneumonia

D. Lillicrap, 2020, Journal of Thrombosis and Haemostasis.

The Assessment of Carrier Status of Canine Hemophilia A in a Hemophilic Colony.

Tomoko Matsumoto, D. Lillicrap, M. Shima, 2002 .

Practical Hemostasis and Thrombosis: Key/Practical Hemostasis and Thrombosis

M. Makris, N. Key, D. Lillicrap, 2010 .

hemophilia B Leyden mutations acting elements and the deleterious effects of naturally occurring Transcriptional control of the factor IX gene: analysis of five cis-

D. Lillicrap, C. Mueller, D. Picketts, 2011 .

Transcriptional control of the factor IX gene: analysis of five cis-acting elements and the deleterious effects of naturally occurring hemophilia B Leyden mutations.

D. Lillicrap, C. Mueller, D. Picketts, 1994, Blood.

Synergy between transcription factors DBP and C/EBP compensates for a haemophilia B Leyden factor IX mutation

D. Lillicrap, C. Mueller, D. Picketts, 1993, Nature Genetics.

von Willebrand factor propeptide variants lead to impaired storage and ER retention in patient‐derived endothelial colony‐forming cells

A. Iorio, D. Lillicrap, A. Tuttle, 2022, Journal of thrombosis and haemostasis : JTH.

Current Understanding of Inherited Modifiers of FVIII Pharmacokinetic Variation

D. Lillicrap, L. Swystun, 2023, Pharmacogenomics and personalized medicine.

The future of basic science research into a leading cause of disability and death

D. Lillicrap, J. Morrissey, 2022, Journal of thrombosis and haemostasis : JTH.

Syntaxin-binding protein 5 exocytosis regulation: differential role in endothelial cells and platelets.

D. Lillicrap, 2014, The Journal of clinical investigation.

Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease.

H. White, C. Byrne, M. Othman, 2004, Blood.

Multifaceted pathomolecular mechanism of a VWF large deletion involved in the pathogenesis of severe VWD

M. Jamil, J. Oldenburg, O. el-Maarri, 2021, Blood advances.

The Endothelial Lectin Receptor CLEC4M Internalizes Factor VIII and Von Willebrand Factor Via a Clathrin-Coated Pit-Dependent Mechanism

P. James, D. Lillicrap, C. Notley, 2013 .

The highly prevalent deletions in F8 intron 13 found in French mild hemophilia A patients result from both founder effect and recurrent de novo events

C. Négrier, D. Lillicrap, C. Vinciguerra, 2018, Journal of thrombosis and haemostasis : JTH.

von Willebrand Factor Is a Critical Mediator of Deep Vein Thrombosis in a Mouse Model of Diet-Induced Obesity

P. Lenting, D. Lillicrap, J. Mewburn, 2020, Arteriosclerosis, thrombosis, and vascular biology.

A sticky proposition: The endothelial glycocalyx and von Willebrand factor

D. Lillicrap, Seon Jae Choi, 2020, Journal of thrombosis and haemostasis : JTH.

The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity

S. Goerdt, R. Montgomery, P. James, 2018, The Journal of clinical investigation.

Longitudinal bleeding assessment in von Willebrand disease utilizing an interim bleeding score

R. Montgomery, P. Christopherson, P. James, 2022, Journal of thrombosis and haemostasis : JTH.

Expanded phenotype–genotype correlations in a pediatric population with type 1 von Willebrand disease

V. Blanchette, M. Carcao, P. James, 2011, Journal of thrombosis and haemostasis : JTH.

A survey of recommendations by gynecologists in Canada regarding oral contraceptive use in the perioperative period.

R. Reid, D. Lillicrap, P. Hahn, 2002, American journal of obstetrics and gynecology.

Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models.

D. Lillicrap, Kate Sponagle, C. Notley, 2011, Blood.

Carrier detection and prenatal diagnosis of Pelizaeus-Merzbacher disease using a combination of anonymous DNA polymorphisms and the proteolipid protein (PLP) gene cDNA.

D. Lillicrap, P. Macleod, P. Bridge, 1991, American journal of medical genetics.

Molecular diagnosis of the fragile X [Fra (X)] syndrome: calculation of risks based on flanking DNA markers in small phase-unknown families.

D. Lillicrap, P. Bridge, 1989, American journal of medical genetics.

Relapse of acute myelogenous leukemia presenting with extrahepatic obstruction of the biliary tract.

D. Lillicrap, A. D. Ginsburg, W. Corbett, 1982, Canadian Medical Association journal.

von Willebrand disease biology

M. Blombäck, D. Lane, J. Eikenboom, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

The molecular genetics of von Willebrand disease

D. Lillicrap, 2009 .

Changes

D. Lillicrap, James H. Morrissey, 2020, Journal of thrombosis and haemostasis : JTH.

Desmopressin responsiveness by age in type 1 von Willebrand disease

R. Nisenbaum, P. James, J. Teitel, 2020, Research and practice in thrombosis and haemostasis.

DNA microarray analysis for the detection of mutations in hemophilia A

H. Feilotter, J. Leggo, D. Lillicrap, 2006, Journal of thrombosis and haemostasis : JTH.

Cardiac Decellularisation With Long-Term Storage and Repopulation With Canine Peripheral Blood Progenitor Cells †,‡

Sandeep T. Koshy, D. Lillicrap, J. G. Guillemette, 2012 .

Human von Willebrand Disease Mutations in Mouse von Willebrand Factor Alter Its Cleavage by ADAMTS13.

D. Lillicrap, C. Notley, C. Hegadorn, 2007 .

AAV immunity: more than meets the eye

D. Lillicrap, 2006 .

Prothrombotic disorders in infants and children with cerebral thromboembolism.

G. deVeber, P. Monagle, D. MacGregor, 1998, Archives of neurology.

Direct detection of a common inversion mutation in the genetic diagnosis of severe hemophilia A [see comments]

D. Lillicrap, S. Taylor, S. Windsor, 1994 .

Direct detection of a common inversion mutation in the genetic diagnosis of severe hemophilia A.

D. Lillicrap, S. Taylor, S. Windsor, 1994, Blood.

The challenge of genetically unresolved haemophilia A patients: Interest of the combination of whole F8 gene sequencing and functional assays

S. Susen, J. Goudemand, J. Gauthier, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

A Founder Factor VII Mutation, Valine 2016 to Alanine, in a Population with an Extraordinarily High Prevalence of Mild Hemophilia A

J. Leggo, D. Lillicrap, M. Scully, 2002, Thrombosis and Haemostasis.

Haemophilia: strategies for carrier detection and prenatal diagnosis.

R. Ljung, D. Lillicrap, I. Peake, 1993, Bulletin of the World Health Organization.

MULTIPLE Xba I POLYMORPHISMS IN HAEMOPHILIA A

Sherryl A. M. Taylor, V. Chan, T. Chan, 1990, British journal of haematology.

Low von Willebrand factor phenotype: the enigma continues.

D. Lillicrap, 2022, Blood.

Induction of Immune Tolerance to Canine FVIII in Hemophilia a Dogs with Inhibitors Using AAV-Mediated Expression of Canine FVIII

H. Kazazian, M. Ozelo, T. Nichols, 2008 .

Von Willebrand: the scientist, the disease, the factor, and the treatment.

D. Lillicrap, E. Berntorp, 2007, Thrombosis research.

493. Induction of Long-Term Immune Tolerance for Neo-Antigens Following Gene Therapy with High-Capacity Adenoviral Vectors by Transient Elimination of Kupffer Cells

S. Kochanek, N. Rooijen, G. Schiedner, 2003 .

Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: A EHA Consensus Report

P. Noris, A. Tosetto, F. Leebeek, 2019 .

Assembly of alternative prothrombinase by extracellular histones initiate and disseminate intravascular coagulation.

D. Lillicrap, J. Foley, C. Toh, 2020, Blood.

Differential termination of primer extension: a novel, quantifiable method for detection of point mutations

D. Lillicrap, S. Taylor, C. Cameron, 1992, Human Genetics.

Quantitation of Bleeding Symptoms in Children with von Willebrand Disease (VWD) or a Platelet Function Disorder: Use of a Standardized Pediatric Bleeding Score.

V. Blanchette, P. James, D. Lillicrap, 2007 .

Moderate-intensity aerobic exercise versus desmopressin in adolescent males with mild hemophilia A: a randomized trial.

B. Kerlin, M. Carcao, V. Bouskill, 2022, Blood.

Exome Sequencing Studies Identify Mutations in STAB2 As a Genetic Risk for Venous Thromboembolic Disease

D. Goldstein, Jun Z. Li, P. Reitsma, 2017 .

A Novel Von Willebrand Factor Fragment Acts As a Chaperone to Prolong the Half-Life of Recombinant Human FVIII (Simoctocog Alfa) in Hemophilia a Dogs and FVIII/VWF Double Knockout Mice

D. Lillicrap, C. Hough, C. Kannicht, 2017 .

Prevention of Anti-FVIII Inhibitor Formation Post Protein Infusion in Hemophilic Mice by Prior Feeding of the FVIII-C2 Domain.

E. Davie, D. Lillicrap, F. E. Rawle, 2004 .

Immune complications and their management in inherited and acquired bleeding disorders

R. Herzog, V. Arruda, D. Lillicrap, 2022, Blood.

Monitoring protein and transgene activities , use of Thromboelastograms and thrombin generation assays

D. Lillicrap, 2008 .

Biological considerations of plasma-derived and recombinant factor VIII immunogenicity.

J. Tarrant, D. Lillicrap, C. Hough, 2017, Blood.

Synthesis of FVIII in Hemophilia-A patients with the intron-22-inversion may modulate immunogenicity

C. Yanover, T. Przytycka, J. Curran, 2013, Nature Medicine.

Generation and validation of the Condensed MCMDM‐1VWD Bleeding Questionnaire for von Willebrand disease

P. James, W. Hopman, D. Lillicrap, 2008, Journal of thrombosis and haemostasis : JTH.

Undetected factor VIII in a patient with type 3 von Willebrands disease mistaken as severe haemophilia A

D. Lillicrap, I. Walker, M. Pai, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

The prevalence of symptomatic von Willebrand disease in primary care practice

P. James, W. Hopman, D. Lillicrap, 2010, Journal of thrombosis and haemostasis : JTH.

Challenges in diagnosis of von Willebrand disease in the presence of combined mutations of different genes

J. Gauthier, D. Lillicrap, A. Bonnefoy, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Analysis of the role of von Willebrand factor, platelet glycoprotein VI-, and α2β1-mediated collagen binding in thrombus formation.

B. Nieswandt, D. Lillicrap, Kate Sponagle, 2014, Blood.

DIAGNOSTIC EFFICACY OF SYSTEMATIC INVESTIGATION OF NON-VON WILLEBRAND BLEEDERS: RESULTS OF A PROSPECTIVE STUDY

P. James, D. Lillicrap, M. Bowman, 2007 .

Hierarchical scaffold design for mesenchymal stem cell-based gene therapy of hemophilia B.

A. Yousefi, M. Blostein, Rouwayda El Ayoubi, 2011, Biomaterials.

Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.

M. Othman, D. Lillicrap, C. Hough, 2009, Blood.

The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels.

D. Lillicrap, Kate Sponagle, N. Rydz, 2013, Blood.

Early Intraoperative Blood Collection Does Not Affect Complete Blood Counts, von Willebrand Factor or Factor VIII Levels in Normal Children

D. Lillicrap, M. Silva, P. James, 2011, Journal of pediatric hematology/oncology.

THE BASIC SCIENCE , DIAGNOSIS , AND CLINICAL MANAGEMENT OF VON WILLEBRAND DISEASE

S. Schulman, D. Lillicrap, 2008 .

Theoretical structural explanation for Group I and Group II, type 2A von Willebrand disease mutations

J. Sutherland, L. O'Brien, D. Weaver, 2005, Journal of thrombosis and haemostasis : JTH.

C. Miao, T. VandenDriessche, M. Chuah, 2009, Blood.

Risk of venous thromboembolism associated with the common hereditary haemochromatosis Hfe gene (C282Y) mutation

T. Baglin, D. Lillicrap, S. Taylor, 1999, British journal of haematology.

von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.

D. Lillicrap, 2013, Blood.

Adeno-associated viruses for gene therapy - clinical implications and liver related complications, a guide for hepatologists.

D. Lillicrap, Stefan Zeuzem, Sylvia Fong, 2023, Journal of hepatology.

Lipid nanoparticles and siRNA targeting plasminogen provide lasting inhibition of fibrinolysis in mouse and dog models of hemophilia A

C. Kastrup, T. Bugge, A. Wolberg, 2024, Science Translational Medicine.